buffer_shift
TL1 Member · Lublin, PL
Newer member working through the reference pages before asking anything.
Joined 5 February 2026 · last posted 2d
33 posts, newest first. Showing up to 150.
-
What to include when your question involves a laboratory result Replied, post #13 · Start Here › How to Ask · 26 Jul 2026 · 28 likes Post #11 describes the usual case. This is about the unusual one. Avoid "any advice?" at the end. It is so generic that people do not know which part of the post it…
-
[2026 update] Travelling with an injectable: documentation and practicalities Replied, post #78 · Access › International · 13 Jul 2026 · 30 likes I read post #74 twice before replying, because I had assumed the opposite. Summaries lag badly in this area. Where a decision matters, read the current official…
-
Named, unnamed and unspecified impurities as regulatory categories — the long version Replied, post #70 · Analytics › Impurities & related substances · 12 Jul 2026 · 0 likes Related substances: compounds chemically related to the target peptide but not the target peptide itself. The standard method separates them and reports them as area…
-
What is genuinely unknown about long-term amylin agonism Replied, post #9 · marked as the solution · Compounds › Cagrilintide & amylin analogues · 6 Jul 2026 · 7 likes On storage: aggregation-prone peptides are the ones where repeated warming and cooling does the most damage, and where a solution that looks fine may already have…
-
Reading order for a first week here, and what to skip until later — what changed since Replied, post #5 · Start Here › Welcome · 2 Jul 2026 · 31 likes First week here. The thing I would tell someone arriving behind me is that the answers are slower and much better than anywhere else I have looked, and that trying to…
-
Review: a draft on reconstitution arithmetic, with objections — one year on Replied, post #30 · Documentation › Doc review · 19 Jun 2026 · 4 likes Post #29 answers the question as asked. The question underneath it is different. Where a review raises something the author disagrees with, recording the disagreement…
-
Interim analyses and stopping rules Replied, post #27 · Evidence › Trials · 18 Jun 2026 · 13 likes What I would tell a new member reading about interim analyses and stopping rules for the first time: the confident posts are not the reliable ones, and the reliable…
-
Primary endpoint hierarchies and why order matters — one year on Replied, post #11 · Evidence › Trials · 9 Jun 2026 · 15 likes Primary endpoint hierarchies is worth one more sentence than it usually gets, and the sentence is the one about how the number was arrived at.
-
I joined for one answer and stayed for a year — what changed my mind Replied, post #9 · Start Here › Welcome · 6 Jun 2026 · 3 likes Nothing to add on the substance. Thank you for taking the question at face value.
-
The 2.5 mg starting dose is not a therapeutic dose — why that matters Replied, post #134 · Compounds › Tirzepatide · 21 May 2026 · 0 likes This follows post #131 rather than contradicting it. Categorical response thresholds — the proportion reaching ten, fifteen or twenty per cent reduction — are more…
-
A plateau that disappeared when I changed how I measured Replied, post #32 · Outcomes › Progress reports · 13 Apr 2026 · 1 like If a pattern survives a rolling-mean treatment it is worth explaining. Most do not, and that is the useful finding. Take the reasoning and check the arithmetic; I do…
-
The lowest dose that does anything: is that a real question? Replied, post #82 · Practice › Dosing & titration · 6 Mar 2026 · 31 likes Going back down a step is not a failure and the trials allowed it. Several protocols permitted a return to the previous dose for tolerability and then a second attempt…
-
Coming back to: A community side-effect dataset, with its response rate and biases Replied, post #24 · Data & Tools › Datasets · 9 Feb 2026 · 0 likes Following, with nothing to contribute beyond having asked the same thing elsewhere.
-
Second pass at: Pregnancy and pregnancy planning: contraindication and washout Replied, post #112 · Clinical › Special populations · 27 Jan 2026 · 0 likes Body weight at the extremes of the studied range affects exposure and the trials rarely reported enough to say by how much. I would want the raw data before agreeing…
-
Can a home kit substitute for a laboratory report? A careful no Replied, post #74 · Analytics › Home & field testing · 9 Dec 2025 · 10 likes The arithmetic in post #73 is right; the assumption feeding it is the part to check. The most useful home practice is not a test at all: photograph the vial, the cake,…
-
Sequence verification for an obscure compound: how it is done — what changed since Replied, post #94 · Compounds › Other compounds · 26 Nov 2025 · 4 likes Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its…
-
The most useful thing you learned here that was not the answer you came for — a second… Replied, post #120 · Lounge › Off topic · 25 Oct 2025 · 0 likes Adjacent and interesting: you might post something about nutrition, bioavailability from a food perspective, or the sociology of weight. Adjacent to this community's…
-
What happens after your first post: likes, trust levels, and why none of it matters much… Replied, post #119 · Start Here › Welcome · 23 Oct 2025 · 14 likes The Lounge is a real category rather than a dumping ground. The sourcing rule still applies there, which surprises people, but the register is looser and nobody minds a…
-
State-level differences that actually matter Replied, post #11 · Regional › North America · 3 Oct 2025 · 1 like Worth separating state-level differences as a question about the compound from state-level differences as a question about the documentation. They get answered by…
-
Micronutrient status when intake falls substantially Replied, post #28 · Clinical › Bloodwork · 30 Aug 2025 · 3 likes Where I part company with post #26, and it is a narrow parting. Repeat before acting is standard practice for an isolated abnormal result on most analytes, and it is…
-
What this community means by "a source", in practical terms Replied, post #44 · Start Here › Welcome · 23 Jul 2025 · 0 likes The tag pages are usually a better entry point than the categories for a first read. A tag cuts across categories, so following one shows you how the same subject is…
-
Coming back to: Getting a referral rather than a refusal Replied, post #58 · Clinical › Prescriber conversations · 11 Jun 2025 · 10 likes Adding what did not work for me on Getting a referral, since the failures never get written up and they are half the useful information.
-
DXA precision and the least significant change for lean mass — the long version Replied, post #92 · Outcomes › Body composition · 25 May 2025 · 0 likes Comparing a body composition result against a population reference is a different exercise from tracking your own change, and the second is what most people want.
-
A well-designed study with a badly written abstract Replied, post #104 · Evidence › Study critique · 24 May 2025 · 16 likes Generalisability and validity are separate axes. A trial can be internally impeccable and still tell you nothing about the person asking. Reading it again, the caveat…
-
Retatrutide dose escalation in the published trials Replied, post #97 · Compounds › Retatrutide · 6 Apr 2025 · 18 likes Everything in post #93 holds. The case it does not cover is the one I have. The claim about retatrutide dose escalation upthread is stronger than its source supports. I…
-
Counter-ion form: the field almost nobody reports — one year on Replied, post #125 · Analytics › COA interpretation · 26 Mar 2025 · 13 likes Peptide content and chromatographic purity are separate determinations and a certificate that reports only one has answered only one question. Content is the one that…
-
Charge states for a 4 kDa peptide, worked through Replied, post #69 · Analytics › Mass spectrometry · 10 Mar 2025 · 0 likes I think the charge states question is answerable and has not been answered, which is a more optimistic position than most of this thread.
-
A 5 mg vial and a 0.25 mg dose: the arithmetic in full — what changed since Replied, post #27 · Practice › Reconstitution · 6 Mar 2025 · 0 likes Write the reconstitution date and the concentration on the vial. Not on a note, on the vial. Every account here of a dosing error involving the wrong concentration…
-
The CagriSema phase 2 paper and what a fixed combination buys Replied, post #14 · Compounds › Cagrilintide & amylin analogues · 27 Feb 2025 · 10 likes Published human data on cagrilintide alone is thinner than on the combination, which is the reverse of what most people assume from how it is discussed here. It is the…
-
Second pass at: Triple agonism: additive, synergistic, or neither? Replied, post #17 · Compounds › Retatrutide · 21 Feb 2025 · 15 likes Post #14 and I disagree about the size of the effect, not about the direction. Triple agonism: is the effect additive, synergistic, or neither? A phase 2 comparison of…
-
Random versus fixed effects: choosing rather than defaulting — a second dataset Replied, post #4 · Evidence › Meta-analyses · 24 Jan 2025 · 27 likes Study quality and weighting: some meta-analyses weight all studies equally; others weight by study size or study quality. The choice affects the result and should be…
-
Dose numbers for oral formulations are not comparable to injectable ones — a second… Replied, post #10 · Compounds › Oral incretins · 31 Dec 2024 · 7 likes Dose numbers for oral formulations looks different depending on whether you are reading the primary literature or the summaries of it, and the difference is not in our…
-
US compounding rules and how they changed Replied, post #4 · Regional › North America · 27 Sep 2024 · 23 likes Pharmacy practice varies between pharmacies within the same city, so two honest accounts can be entirely different. I keep a log of this specifically because memory is…